NEW YORK – Researchers from Ambry Genetics have published important validation data for the targeted RNA-seq addition the company made to its hereditary cancer test services last fall, concluding that obtaining RNA splicing data parallel to DNA enables the identification of pathogenic variants that would have been either missed or classified as inconclusive with DNA testing alone.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.